Featured Research

from universities, journals, and other organizations

Immune Therapy Appears To Reduce Risk Of Second Attack Of Multiple Sclerosis Symptoms

Date:
October 14, 2004
Source:
Journal Of The American Medical Association
Summary:
Intravenous immunoglobulin therapy may reduce the risk of a second attack of symptoms related to multiple sclerosis, according to an article in the October issue of The Archives of Neurology, one of the JAMA/Archives journals.

Intravenous immunoglobulin therapy may reduce the risk of a second attack of symptoms related to multiple sclerosis, according to an article in the October issue of The Archives of Neurology, one of the JAMA/Archives journals.

According to the article, multiple sclerosis (MS) is a chronic, inflammatory disease characterized by demyelinization of the brain and spinal cord. Myelin is a material that covers and insulates nerve cells, and allows signals to travel from cell to cell. The onset of MS is defined by having neurological impairment related to motor, sensory, cerebellar, visual, brainstem or cognitive functioning, as well as having symptoms of urinary tract dysfunction, the article states. Intravenous immunoglobulin (IVIg) has been reported to diminish the symptoms of MS in patients with relapsing-remitting MS (where symptoms flare up and then disappear later). The progression of MS is affected by the time to occurrence of the second neurological event, as well as the number of events within the first year.

Anat Achiron, M.D., Ph.D., of Sheba Medical Center, Tel-Hashomer, Israel, and colleagues assessed the effect of IVIg treatment in patients after the first neurological event suggestive of MS and evaluated the occurrence of a second attack.

Ninety-one patients (average age, 33.9 years) who experienced neurological symptoms indicative of MS for the first time enrolled in the study within six weeks of their symptoms. Patients were randomly assigned to receive IVIg treatment, or placebo, given once every six weeks for one year. Neurological and clinical assessments were performed every three months, and brain magnetic resonance imaging (MRI) was performed at the beginning and end of the study.

The researchers found that the probability of developing clinically definite multiple sclerosis was significantly lower in the IVIg treated group compared with patients in the placebo group. Patients in the IVIg group also had fewer brain lesions as seen on MRIs.

"Intravenous immunoglobulin treatment for the first year from onset of the first neurological event suggestive of demyelinative disease significantly lowers the incidence of a second attack and reduces disease activity as measured by brain magnetic resonance imaging," the authors write.

(Arch Neurol. 2004;61:1515-1520. Available post-embargo at archneurol.com)

Editor's Note: This study was supported by a research grant from Omrix Biopharmaceuticals. Tel-Aviv, Israel, which also supplied the study drugs (intravenous immunoglobulin and placebo). The authors have no financial relationship to Omrix Biopharmaceuticals.


Story Source:

The above story is based on materials provided by Journal Of The American Medical Association. Note: Materials may be edited for content and length.


Cite This Page:

Journal Of The American Medical Association. "Immune Therapy Appears To Reduce Risk Of Second Attack Of Multiple Sclerosis Symptoms." ScienceDaily. ScienceDaily, 14 October 2004. <www.sciencedaily.com/releases/2004/10/041012085337.htm>.
Journal Of The American Medical Association. (2004, October 14). Immune Therapy Appears To Reduce Risk Of Second Attack Of Multiple Sclerosis Symptoms. ScienceDaily. Retrieved October 22, 2014 from www.sciencedaily.com/releases/2004/10/041012085337.htm
Journal Of The American Medical Association. "Immune Therapy Appears To Reduce Risk Of Second Attack Of Multiple Sclerosis Symptoms." ScienceDaily. www.sciencedaily.com/releases/2004/10/041012085337.htm (accessed October 22, 2014).

Share This



More Health & Medicine News

Wednesday, October 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Orthodontist Mom Jennifer Salzer on the Best Time for Braces

Working Mother (Oct. 22, 2014) Is your child ready? Video provided by Working Mother
Powered by NewsLook.com
U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

U.S. Issues Ebola Travel Restrictions, Are Visa Bans Next?

Newsy (Oct. 22, 2014) Now that the U.S. is restricting travel from West Africa, some are dropping questions about a travel ban and instead asking about visa bans. Video provided by Newsy
Powered by NewsLook.com
US to Track Everyone Coming from Ebola Nations

US to Track Everyone Coming from Ebola Nations

AP (Oct. 22, 2014) Stepping up their vigilance against Ebola, federal authorities said Wednesday that everyone traveling into the US from Ebola-stricken nations will be monitored for symptoms for 21 days. (Oct. 22) Video provided by AP
Powered by NewsLook.com
Doctors Help Paralysed Man Walk Again, Patient in Disbelief

Doctors Help Paralysed Man Walk Again, Patient in Disbelief

AFP (Oct. 22, 2014) Polish doctors describe how they helped a paralysed man walk again, with the patient in disbelief at the return of sensation to his legs. Duration: 1:04 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:

Strange & Offbeat Stories


Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins